The results of the PredART trial have been published in the New England Journal of Medicine.
Researchers from UCT and the Institute of Tropical Medicine (Belgium) have shown that a four-week course of moderate dose prednisone reduced the risk of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) by 30% in HIV-positive patients. This is the first trial to show that TB-IRIS can be prevented in these patients and represents an important contribution to the body of knowledge on management of HIV-TB co-infection.
TB-IRIS is a serious risk in people living with HIV, resulting in hospitalisation of a quarter of people who experience it. The syndrome occurs in 18% of patients with HIV-associated TB initiating antiretroviral therapy.